Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

The AARP report suggests the spending cap could be huge for Medicare enrollees who take costly drugs for cancer, rheumatoid arthritis, and other conditions.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Findings show the impact of drug companies’ relentless price increases, underscoring the importance of the changes included in the historic 2022 drug law.

"Brand-name drug prices have been increasing faster than the rate of general inflation for decades, putting life-saving medications out of reach for millions of patients who need them," said Leigh ...

New AARP Report Finds Medicare Part D Enrollees Who Reach the New $2,000 Out-of-Pocket Spending Cap Will Save Thousands ...

AARP is a nonprofit membership organization. It offers Medicare supplement insurance plans through UnitedHealthcare. The plans, also known as Medigap, help people pay for out-of-pocket medical ...

"AARP was instrumental in Congress passing the prescription drug law of 2022 to lower prices and out-of-pocket costs for Medicare enrollees and we couldn't be prouder that the day has finally ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

In today’s “AARP Minute,” a new report shows how much money some Medicare enrollees may save this year, plus why cancer rates may be increasing for some older women.

This guide provides step-by-step instructions for shopping and finding the best options for your budget and needs.

Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated ...